Edition:
United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

26.70USD
19 Oct 2017
Change (% chg)

$-0.35 (-1.29%)
Prev Close
$27.05
Open
$26.75
Day's High
$27.10
Day's Low
$26.35
Volume
464,373
Avg. Vol
798,713
52-wk High
$33.00
52-wk Low
$13.60

Batycky, Richard 

DR. Richard P. Batycky is Chief Technology Officer and Site Head of the Company. He joined Acorda as part of the Company’s acquisition of Civitas Therapeutics, which Dr. Batycky co-founded, serving as Chief Scientific Officer. Dr. Batycky has close to two decades of experience in drug development, with a focus on inhaled therapies. Prior to founding Civitas, Dr. Batycky was the Chief Scientific Officer and Sr. Vice President of Research & Development at Pulmatrix. He was previously the Vice President of Research and Development at Alkermes, overseeing many facets of product development across pulmonary, injectable and oral platforms. Dr. Batycky was an original member of Advanced Inhalation Research (AIR®), where he oversaw product development utilizing the ARCUS® technology for pulmonary delivery. Acorda has global development rights to the ARCUS technology as part of the Civitas acquisition. Dr. Batycky held several academic posts prior to joining AIR. Dr. Batycky received his B.Sc. in Chemical Engineering from University of Calgary and his S.M. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen

3,433,220

Richard Batycky

--

David Lawrence

1,360,800

Andrew Blight

1,484,560

Jane Wasman

1,986,540

Burkhard Blank

3,521,550
As Of  30 Dec 2016